S&P 500NASDAQ-100

Regeneron Pharmaceuticals (REGN) — 10-Year DCF Projection Model

Free stock research tool. Build a 10-year revenue, earnings (EPS), and free cash flow forecast for Regeneron Pharmaceuticals (REGN) stock, a company in the Health Care (Biotechnology) sector. Pulls audited SEC EDGAR XBRL financials, triangulates Wall Street analyst consensus across Yahoo Finance, NASDAQ, and StockAnalysis, and overlays AI-clustered news + social event probabilities directly onto projected EPS. For equity research — not personal budgeting or accounting.

Build REGN projection model →Browse all stocks

Regeneron Pharmaceuticals at a glance

Ticker
REGN
Company
Regeneron Pharmaceuticals
Sector
Health Care
Sub-industry
Biotechnology
Headquarters
Tarrytown, New York
Founded
1988
Added to S&P 500
2013-05-01
Index membership
S&P 500, NASDAQ-100

What you'll see in your REGN model

  • 10 years of audited historical financials for Regeneron Pharmaceuticals, sourced directly from the SEC's EDGAR XBRL filings (10-K and 10-Q).
  • Triangulated Wall Street consensus for REGN's forward revenue, EBITDA, and EPS across Yahoo Finance, NASDAQ, and StockAnalysis with cross-source dispersion (σ).
  • AI Event Factors: top-10 news/social themes for REGN with probability sliders and live EPS impact.
  • Sensitivity tables and Excel export for every assumption.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NYSE/NASDAQ: REGN) was founded in 1988 and is headquartered in Tarrytown, New York. The company operates in the Health Care sector (Biotechnology sub-industry) and is a constituent of the S&P 500 and NASDAQ-100. Our projection model builds a clean discounted-cash-flow view of Regeneron Pharmaceuticals in roughly five seconds and lets you adjust every assumption to test your own thesis.